Belantamab mafodotin-blmf


Belantamab mafodotin-blmf

Drug updated on 11/14/2023

Dosage FormInjection (intravenous: 100 mg)
Drug ClassMultiple
Ongoing and
Completed Studies


  • For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Product Monograph / Prescribing Information

Document TitleYearSource
Blenrep (belantamab mafodotin-blmf) Prescribing Information.2022GlaxoSmithKline, Research Triangle Park, NC

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines